ESC 365 - Anti-thrombotics in patients at simultaneous risk of stroke and stent thrombosis

ACVC Premium Access

Anti-thrombotics in patients at simultaneous risk of stroke and stent thrombosis

Event: Acute Cardiovascular Care 2018

Topic: Cardiovascular Pharmacotherapy

Session type: Symposium

Date: 4 March 2018

Time: 11:00 - 12:30

Session

5 presentations in this session

Why do we need to combine antiplatelets and anticoagulants?

Speaker: Professor R. De Caterina (Pisa, IT)

Rational to remove aspirin from the cocktail. The story after WOEST...(VIA ZOOM)

Speaker: Professor J. ten Berg (Nieuwegein, NL)

What have we learned in the era of NOACs.

Speaker: Professor F. Verheugt (Amsterdam, NL)

Type of stent, type of antiplatelet, type of anticoagulant. The triad of success.

Speaker: Doctor G. Casella (Bologna, IT)

Ultra-low-dose twice-daily aspirin improves haemostasis and maintains platelet inhibition in acute coronary syndrome patients receiving ticagrelor

Speaker: Doctor W. Parker (Sheffield, GB)

5 speakers from this session

Professor Raffaele De Caterina

University Hospital of Pisa, Pisa (Italy)

25 presentations

1 follower

Professor Jurrien M ten Berg

St Antonius Hospital, Nieuwegein (Netherlands (The))

15 presentations

0 follower

Professor Freek Verheugt

Onze Lieve Vrouwe Gasthuis, Amsterdam (Netherlands (The))

21 presentations

0 follower

Doctor Gianni Casella

Maggiore Hospital, Department of Cardiology, Bologna (Italy)

1 presentation

0 follower

Doctor William Parker

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

0 follower

This platform is supported by